MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy

Annals of Surgery

Volumn 251, Issue 4, 2010, Pages 701-707

  Straver, Marieke E ^a   Loo, Claudette E ^b   Rutgers, Emiel J T ^a   Oldenburg, Hester S A ^a   Wesseling, Jelle ^c   Vrancken Peeters, Marie Jeanne T F D ^a   Gilhuijs, Kenneth G A ^b  

^a Departments of Surgical Oncology   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PREDICTIVE VALIDITY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; PREDICTIVE VALUE OF TESTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 77950862561     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181c5dda3     Document Type: Article

References (25)

1. Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 2007;94:1189-1200.
2. Chagpar AB, Studts JL, Scoggins CR, et al. Factors associated with surgical options for breast carcinoma. Cancer. 2006;106:1462-1466.
3. Chen JH, Feig BA, Hsiang DJ, et al. Impact of MRI-evaluated neoadjuvant chemotherapy response on change of surgical recommendation in breast cancer. Ann Surg. 2009;249:448-454.
4. Cocconi G, Di Blasio B, Alberti G, et al. Problems in evaluating response of primary breast cancer to systemic therapy. Breast Cancer Res Treat. 1984; 4:309-313.
5. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology. 1988;169:49-54.
6. Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006;243:257-264.
7. Boetes C, Mus RD, Holland R, et al. Breast tumors: comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology. 1995;197:743-747.
8. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roent-genol. 2003;181:1275-1282.
9. Bhattacharyya M, Ryan D, Carpenter R, et al. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer. Br J Cancer. 2008;98:289-293.
10. Segara D, Krop IE, Garber JE, et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol. 2007;96:474-480.
11. Rieber A, Brambs HJ, Gabelmann A, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002;12:1711-1719.
12. Loo CE, Teertstra HJ, Rodenhuis S, et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol. 2008;191:1331-1338.
13. Gilhuijs KG, Deurloo EE, Muller SH, et al. Breast MR imaging in women at increased lifetime risk of breast cancer: clinical system for computerized assessment of breast lesions initial results. Radiology. 2002;225:907-916.
14. Turnbull LW. Magnetic resonance imaging in breast cancer: results of the COMICE trial. Breast Cancer Res. 2008;10:10.
15. Pengel KE, Loo CE, Teertstra HJ, et al. The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat. 2009;116:161-169.
16. Mauriac L, Durand M, Avril A, et al. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991;2:347-354.
17. Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer. 2008;112:17-26.
18. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. In press.
19. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13: 2329-2334.
20. Denis F, Desbiez-Bourcier AV, Chapiron C, et al. Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadju-vant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol. 2004;30:1069-1076.
21. Chen JH, Baek HM, Nalcioglu O, et al. Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging. 2008;27:825-833.
22. Warren RM, Bobrow LG, Earl HM, et al. Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? Br J Cancer. 2004;90:1349-1360.
23. Sadetzki S, Oberman B, Zipple D, et al. Breast conservation after neoadjuvant chemotherapy. Ann Surg Oncol. 2005;12:480-487.
24. Garimella V, Qutob O, Fox JN, et al. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33:157-161.
25. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005;103:689-695.